Distribusion Technologies | $80,000,000 | (Sep 27, 2024)
Cytix | $2,143,528 | (Sep 27, 2024)
Convergence | $12,000,000 | (Sep 27, 2024)
Certified by Founder
Lodge
Ability Biologics
start up
Canada
- Montreal, Quebec
- 07/12/2023
- Seed
- $12,000,000
Our Mission:
Develop innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.
The premier biotherapeutic targeting company
Our powerful AbiLeap™ discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies of exquisite selectivity and affinity. The antibodies respond to environmental signals within the cellular microenvironment, generating logic-gated therapeutics.
We are dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need.
- Industry Biotechnology Research
- Website https://ability.bio/
- LinkedIn https://www.linkedin.com/company/ability-biologics/about/
SURGAR | $12,288,870 | (Sep 27, 2024)
Quorum | Undisclosed Amount | (Sep 27, 2024)
Prepared | $27,000,000 | (Sep 27, 2024)
AmpUp | $15,000,000 | (Sep 27, 2024)
HighFive | $250,000 | (Sep 27, 2024)
Tetrix | $5,000,000 | (Sep 27, 2024)
The Curling Group | $5,000,000 | (Sep 27, 2024)
AminoChain | $5,000,000 | (Sep 27, 2024)
Gladly | $40,000,000 | (Sep 27, 2024)